Prospective evaluation of Vitamin K2, Raloxifene and their co-administration in osteoporotic rats

Date

2011-07-17

Author

Tasci, A. G.
BİLGİLİ, HASAN
Altunay, H.
Gecit, M. R.
Keskin, Dilek

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

175
views

0
downloads

In this study, therapeutic effects of Vitamin K2, Raloxifene and their co-administration on bone, uterus, blood and weight profiles were investigated with an ovariectomized rat model. Forty Wistar rats were divided into five groups (n = 8): Raloxifene (R), Vitamin K2 (K), Raloxifene + Vitamin K2 (R + K), ovariectomized controls (OVX) and Sham-operated controls (Sham). Treatment began 3 months after ovariectomy. Vitamin K2 and Raloxifene were administered 30 and 1.5 mg/kg/day separately and in combination five times per week for 12 weeks. All treatment groups had significantly higher ultimate strength and energy absorption capacity (P < 0.05) than ovariectomized controls in both femur and tibia. Histological results showed that treatment groups had healthy lumen structure, whereas OVX had degeneration. Adverse effects which were seen in individual treatments (myometrium weakening in K, endometrium weakening in R, and ALP increase in group R) were not observed in the R + K group implying a synergistic effect of these two agents when they are co-administered. According to blood analysis, ALP values were significantly high in Raloxifene-only group (P < 0.0001). This effect is suppressed in the co-administered group. In summary, the groups R. K and R + K had significantly higher ultimate strength and less susceptibility to fracture than ovariectomized controls. In summation, Vitamin K2 treated groups (either in single or combined with Raloxifene) had considerable biomechanical performance and reproductive tissue profile indicating that this agent is prospectively effective in osteoporosis management.

Subject Keywords

Pharmaceutical Science

URI

https://hdl.handle.net/11511/40210

Journal

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

DOI

https://doi.org/10.1016/j.ejps.2011.04.019

Collections

Department of Engineering Sciences, Article

Suggestions

OpenMETU
Core

Comparison of NAT1, NAT2 & GSTT2-2 activities in normal and neoplastic human breast tissues Geylan-SU, YS; Isgor, B; Coban, T; Kapucuoglu, N; Aydintug, S; Iscan, M; Iscan, M; Güray, Nülüfer Tülün (American Society for Pharmacology & Experimental Therapeutics (ASPET), 2006-01-01) In this study, arylamine N-acetyltransferases, NATs (E.C.2.3.1.5) and glutathione-S-transferase-T2-2, GSTT2-2 (E.C.2.5.1.18) enzyme activities in the breast tumor and surrounding tumor-free tissues of 22 female breast cancer patients with infiltrating ductal carcinoma were measured. The possible impacts of grade of malignancy, chemotherapy treatment, estrogen receptor status and menopausal status on all enzyme activities were evaluated. The results showed that, both NAT2 and GSTT2-2 display significant diff...
Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response Kocabas, Banu Bayyurt; Almacioglu, Kubra; Bulut, Esin Alpdundar; Gucluler, Gozde; Tincer, Gizem; Bayik, Defne; Gürsel, Mayda; GÜRSEL, İHSAN (Elsevier BV, 2020-12-01) Nucleic acid-based pattern recognition receptor agonists are effective adjuvants and immunotherapeutic agents. Rather than single applications, ligand combinations could synergistically potentiate immune responses by elevating cytokine and chemokine production via triggering multiple signaling pathways. However, short half-lives of such labile ligands due to nuclease attack and limited cellular uptake due to their structure significantly hamper their in vivo performances. More importantly, simultaneous deli...
Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development Bayyurt, Banu; Tincer, Gizem; Almacioglu, Kubra; Alpdundar, Esin; Gürsel, Mayda; GÜRSEL, İHSAN (Elsevier BV, 2017-02-10) Nucleic acid-based Toll-like receptor (TLR) ligands are promising adjuvants and immunotherapeutic agents. Combination of TLR ligands potentiates immune response by providing synergistic immune activity via triggering different signaling pathways and may impact antigen dependent T-cell immune memory. However, their short circulation time due to nuclease attack hampers their clinical performance. Liposomes offer inclusion of protein and nucleic acid-based drugs with high encapsulation efficiency and drug load...
Advances in CRISPR/Cas9 Technology for in Vivo Translation Cicek, Yagiz Anil; Luther, David C.; Kretzmann, Jessica A.; Rotello, Vincent M. (Pharmaceutical Society of Japan, 2019-03-01) Clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized therapeutic gene editing by providing researchers with a new method to study and cure diseases previously considered untreatable. While the full range and power of CRISPR technology for therapeutics is being elucidated through in vitro studies, translation to in vivo studies is slow. To date there is no totally effective delivery strategy to carry CRISPR components to the target...
Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model Özçelikkale, Altuğ; Noe-Kim, Victoria; Elzey, Bennett D.; Dong, Zizheng; Zhang, Jian-Ting; Kim, Kwangmeyung; Kwon, Ick Chan; Park, Kinam; Han, Bumsoo (Elsevier BV, 2017-11-01) Successful drug delivery and overcoming drug resistance are the primary clinical challenges for management and treatment of cancer. The ability to rapidly screen drugs and delivery systems within physiologically relevant environments is critically important; yet is currently limited due to lack of appropriate tumor models. To address this problem, we developed the Tumor-microenvironment-on-chip (T-MOC), a new microfluidic tumor model simulating the interstitial flow, plasma clearance, and transport of the d...

Citation Formats

A. G. Tasci, H. BİLGİLİ, H. Altunay, M. R. Gecit, and D. Keskin, “Prospective evaluation of Vitamin K2, Raloxifene and their co-administration in osteoporotic rats,” EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, pp. 270–277, 2011, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/40210.